Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.


Journal

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 7 12 2018
medline: 9 4 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

: The objective was to examine the genotypic and phenotypic characteristics of individuals with hereditary factor X deficiency (FXD), a rare autosomal recessive bleeding disorder caused by mutations in the F10 gene located on chromosome 13q34-ter. To date, 149 F10 mutations have been identified as contributory to FXD. Three open-label phase 3 trials enrolled individuals with mild, moderate, or severe FXD. Individuals received plasma-derived factor X concentrate as routine prophylaxis, to treat bleeds, and/or during or after surgery. F10 genotyping was performed (studies 1 and 2) or genotype data was collected at screening (study 3), and identified F10 mutations were compared against the Human Gene Mutation Database to assess novelty. Genotype data were combined to evaluate the number, type, and novelty of the F10 mutations identified. Genotype data were available for 24 of 27 individuals with mild (n = 2), moderate (n = 2), or severe (n = 20) FXD. Analyses identified 22 separate mutations, including 15 missense mutations, 2 deletions, 4 splice site mutations, and 1 nonsense mutation. Sixteen individuals had homozygous mutations; 8 had compound heterozygous mutations. Eleven unique novel mutations (all compound heterozygous) were identified in seven individuals: six missense mutations, three splice site mutations, one exon deletion, and one nonsense mutation. In silico analyses strongly supported the pathogenicity of all novel mutations. The identification of 11 novel F10 mutations provides a substantial contribution to the mutations known to cause FXD.

Identifiants

pubmed: 30507709
doi: 10.1097/MBC.0000000000000787
doi:

Substances chimiques

Factor X 9001-29-0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-41

Auteurs

Michael Mitchell (M)

Molecular Haemostasis & Thrombosis, Viapath Analytics LLP, St. Thomas' Hospital, London.

Michael Gattens (M)

The Cambridge Haemophilia and Thrombophilia Centre, Cambridge University Hospitals, Cambridge, UK.

Kaan Kavakli (K)

Ege University Medicine Faculty, Izmir, Turkey.

Ri Liesner (R)

Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital, London.

Jeanette Payne (J)

Department of Paediatric Haematology, Sheffield.

Miranda Norton (M)

Bio Products Laboratory Ltd., Elstree.

Steven Austin (S)

St. George's Haemophilia Centre, St. George's University Hospitals NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH